Volume 83, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



This study analyzed the effectiveness of active case detection (ACD) for new visceral leishmaniasis (VL) cases. ACD detection was carried out using house to house screening in Bangladesh and India and by neighborhood screening around index cases in Nepal. The percent increase of new VL cases through ACD compared to PCD was 6.7–17.1% in India; 38.8% in Nepal; and 60% in Bangladesh. The screening effort was high in India and Bangladesh (house to house screening) compared to Nepal (index case screening). The additional cost per new VL case detected varied: $50 to $106 in India; $172 in Bangladesh; $262 in Nepal depending on the type of screening staff, transport and training costs. The estimated annual VL incidence in the ACD arm ranged from 315–383 in India; 109 in Bangladesh, and 43 per 100,000 in Nepal. The additional effort and cost rises as disease incidence declines or PCD improves.


Article metrics loading...

Loading full text...

Full text loading...



  1. World Health Organization, 2005. Regional Technical Advisory Group on Kala-azar Elimination. Report of the first meeting, Manesar, Haryana, 20–23 December 2004. New Delhi: Regional Office for South-East Asia.
  2. World Health Organization, 2004. Regional Strategic Framework for Elimination of Kala-azar from the South-East Asia Region (2005–2015). New Delhi: Regional Office for South-East Asia.
  3. Bern C, Chowdhury R, , 2006. The epidemiology of visceral leishmaniasis in Bangladesh: prospects for improved control. Indian J Med Res 23: 275288.
  4. Joshi A, Narain JP, Prasittisuk C, Bhati R, Hashim G, Jorge A, Banjara M, Kroeger A, , 2008. Can visceral leishmaniasis be eliminated from Asia? J Vector Borne Dis 45: 105111.
  5. Desjeux P, , 1996. Leishmaniasis. Public health aspects and control. Clin Dermatol 14: 417423.[Crossref]
  6. Singh SP, Reddy DC, Rai M, Sundar S, , 2006. Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India. Trop Med Int Health 11: 899905.[Crossref]
  7. Bhattacharya SK, Sinha PK, Sundar S, Thakur CP, Jha TK, Pandey K, Das VR, Kumar N, Lal C, Verma N, Singh VP, Ranjan A, Verma RB, Anders G, Sindermann H, Ganguly NK, , 2007. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis 196: 591598.[Crossref]
  8. Sundar S, Jha TK, Thakur CP, Bhattacharya SK, Rai M, , 2006. Oral miltefosine for the treatment of Indian visceral leishmaniasis. Trans R Soc Trop Med Hyg 100 (Suppl 1): S26S33.[Crossref]
  9. Sundar S, Chartterjee M, , 2006. Visceral leishmaniasis–therapeutic modilities. Indian J Med Res 9: 2639.
  10. Sundar S, Reed SG, Singh VP, Kumar PC, Murray HW, , 1998. Rapid accurate field diagnosis of Indian visceral leishmaniasis. Lancet 351: 563565.[Crossref]
  11. Sundar S, Pai K, Sahu M, Kumar V, Murray HW, , 2002. Immunochromatographic striptest detection of anti-rK39 antibody in Indian visceral leishmaniasis. Ann Trop Med Parasitol 96: 1923.[Crossref]
  12. Sarker CB, Momem A, Jamal MF, Siddiqui NF, Chrowdhury KS, Rahman S, Talukder SI, , 2003. Immunochromatographic (rK39) strip test in the diagnosis of visceral leishmaniasis in Bangladesh. Mymensingh Med J 12: 9397.
  13. Bern C, Jha SN, Joshi AB, Thakur GD, Bista MB, , 2000. Use of the recombinant K39 dipstick test and the direct agglutination test in a setting endemic for visceral leishmaniasis in Nepal. Am J Trop Med Hyg 65: 153157.
  14. World Health Organization, 2007. Regional Technical Advisory Group on kala-azar elimination. Report of the Second Meeting, Kathmandu, Nepal, 20 October–2 November 2006. New Delhi: WHO SEARO, WHO Project: CCP CPC 050.
  15. Sundar S, Mondal D, Rijal S, Bhattacharya S, Ghalib H, Kroeger A, Boelacrt M, Desjeux P, Richter-Airijoki H, Harms G, , 2008. Implementation research to support the initiative on the elimination of kala-azar from Bangladesh, India and Nepal–the challenges for diagnosis and treatment. Trop Med Int Health 13: 25.[Crossref]
  16. Mondal D, Singh SP, Kumar N, Joshi A, Sundar S, Das P, Siddivinayak H, Kroeger A, Boelaert M, , 2009. Visceral leishmaniasis elimination program in India, Bangladesh and Nepal: reshaping the case finding/case management strategy. PLoS Negl Trop Dis 3: e355.[Crossref]
  17. Chappuis F, Rijal S, Soto A, Menten J, Boelaert M, , 2006. A meta-analysis of the diagnostic performance of the direct agglutination test and rk39 dipstick for visceral leishmaniasis. BMJ 333: 723726.[Crossref]
  18. Wilson JM, Juenger G, , 1968. Principles and practice of screening for disease. Geneva: World Health Organization, Public Health Papers No. 34.
  19. World Health Organization, 2003. Leprosy elimination campaigns: impact on case detection. Wkly Epidemiol Rec 78: 916.
  20. Napier LE, Das Gupta CR, , 1930. A clinical study of post kala-azar dermal leishmaniasis. Ind Med Gaz 63: 249257.
  21. Thakur CP, , 1984. Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis). Trans R Soc Trop Med Hyg 78: 391398.[Crossref]

Data & Media loading...

  • Received : 14 Nov 2009
  • Accepted : 27 May 2010

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error